These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 22177154)

  • 1. Intravesical bacillus Calmette-Guérin outcomes in patients with bladder cancer and asymptomatic bacteriuria.
    Herr HW
    J Urol; 2012 Feb; 187(2):435-7. PubMed ID: 22177154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette-Guérin?
    Herr H
    Int J Urol; 2020 Jan; 27(1):72-74. PubMed ID: 31661717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer.
    Muto S; Nakajima A; Horiuchi A; Inoue M; China T; Saito K; Isotani S; Hisasue S; Yamaguchi R; Ide H; Horie S
    Jpn J Clin Oncol; 2013 Mar; 43(3):305-13. PubMed ID: 23303841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical bacille Calmette-Guérin eradicates bacteriuria in antibiotic-naïve bladder cancer patients.
    Herr HW
    Eur Urol; 2013 May; 63(5):832-5. PubMed ID: 22921719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of intravesical instillation of antifibrinolytic agents on bacillus Calmette-Guerin treatment of superficial bladder cancer: a pilot study.
    Pan CW; Shen ZJ; Ding GQ
    J Urol; 2008 Apr; 179(4):1307-11; discussion 1311-2. PubMed ID: 18289576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
    Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
    J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
    Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
    J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ; McKiernan JM; Benson MC
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer.
    Nepple KG; Lightfoot AJ; Rosevear HM; O'Donnell MA; Lamm DL;
    J Urol; 2010 Nov; 184(5):1915-9. PubMed ID: 20846688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
    Nativ O; Witjes JA; Hendricksen K; Cohen M; Kedar D; Sidi A; Colombo R; Leibovitch I
    J Urol; 2009 Oct; 182(4):1313-7. PubMed ID: 19683278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V; Pode D; Pikarsky E; Mandelboim O
    J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer.
    Bisiaux A; Thiounn N; Timsit MO; Eladaoui A; Chang HH; Mapes J; Mogenet A; Bresson JL; Prié D; Béchet S; Baron C; Sadorge C; Thomas S; Albert EB; Albert PS; Albert ML
    J Urol; 2009 Apr; 181(4):1571-80. PubMed ID: 19230924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer.
    Cai T; Nesi G; Dal Canto M; Tinacci G; Mondaini N; Piazzini M; Geppetti P; Bartoletti R
    J Urol; 2010 May; 183(5):1738-43. PubMed ID: 20299058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
    J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening urine analysis before bacille Calmette-Guérin instillation does not reduce the rate of infectious complications.
    Zhao LC; Meeks JJ; Helfand BT; Ross FR; Herr HW; Kundu SD
    BJU Int; 2012 Jun; 109(12):1819-21. PubMed ID: 22077819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
    Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
    Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.